GGTOTO| Behind every venture Global Bio Fund backs is a team that's spent decades inside the industries those founders are trying to change. Founding Partner and CEO Ipshita Mandal-Johnson built the fund around a simple observation: women bio-entrepreneurs were producing some of the strongest science in the sector and still struggling to get funded on the same terms as their peers. She leads alongside Founding Partner and CFO Giorgio Reggiani, with a global advisory network that includes Peder Nielsen, former President and CEO of Novozymes, bringing decades of hands-on experience scaling biotech and life-science companies. Together, this team doesn't just write checks — it sits close to the science, the market, and the founders themselves, turning early-stage bio-innovation into ventures built to last.
Ipshita Mandal-Johnson didn't come to this from the investor side first — she came from watching brilliant bio-innovation stall out for reasons that had nothing to do with the science. That experience shaped the fund's founding premise: capital alone doesn't fix a broken pipeline if the people holding it keep overlooking the same pool of talent. As Founding Partner and CEO, she sets that direction across every stage of Global Bio Fund's work, from which ventures get backed to how the fund measures whether its bet on a founder actually paid off.
On the financial side, Founding Partner and CFO Giorgio Reggiani keeps that mission grounded in discipline. Seed funding only helps founders if it's structured well and deployed at the right moments, and Reggiani's role is making sure the fund's capital does exactly that — moving efficiently from commitment to a founder's bank account, without the friction that early-stage ventures can least afford.
Beyond the founding team, Global Bio Fund draws on an advisory network built specifically for the problems its portfolio companies actually face. Peder Nielsen, former President and CEO of Novozymes, brings decades of experience scaling biotech at a global level. Other advisors add depth in healthcare and in women's economic empowerment, so founders get guidance that reflects both the technical realities of their science and the market and funding barriers unique to women-led ventures.
What ties this group together isn't just a shared cap table entry — it's a working relationship with the founders themselves. Through the fund's editorial platform and ongoing advisory touchpoints, the Global Bio Fund team stays close to portfolio companies well past the initial check, offering the kind of hands-on input that turns a promising idea into a venture that can actually scale.